Microdosing GLP-1s The Peoples Court: Case No
however, the use of lixisenatide was associated with more gastrointestinal side effects
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropicGLP-1RAs, have evolved from metabolic therapies to agents with either proven or potential protective effects on the kidney and heart
Lack of response on Sermorelin is sometimes a signal that a longer-half-life GHRH analog or a combination protocol is the more appropriate intervention
Di Lorenzo A, Bolli E, Ruiu R, Ferrauto G, Di Gregorio E, Avalle L, Savino A, Poggio P, Merighi IF, Riccardo F, et al
These include, extreme tiredness, a lack of energy, pins and needles, muscle weakness, disturbed vision, mouth ulcers, a sore and red tongue, and cognitive or psychological concerns such as depression, confusion, and difficulty with memory, understanding or judgement